{"product_id":"prestigeconsumerhealthcare-pestle-analysis","title":"Prestige Consumer Healthcare PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eOur PESTLE Analysis of Prestige Consumer Healthcare reveals how regulatory shifts, consumer trends, and technological advances will shape the company's growth and risk profile. Ideal for investors and strategists, this concise briefing highlights key external drivers and strategic implications. Purchase the full report to access actionable insights and detailed recommendations. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOTC policy and regulator priorities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShifts in FDA, Health Canada and TGA priorities in 2024–25 affect OTC monograph updates, approvals and enforcement intensity, altering time-to-market for line extensions. Faster or slower regulatory review cycles directly change launch timing and working capital needs. Public health agendas such as pain-relief misuse reviews have prompted tighter controls and reformulations. Policy stability supports planning; volatility raises compliance costs and risk-adjusted margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrade and import dynamics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTariffs (typically 2–10% on inputs) and customs bottlenecks that can add days to weeks to lead times materially raise input costs and working capital needs; geopolitical tensions have disrupted API flows and packaging in 2023–24. Stable North America–Australia lanes aid planning but any shock can ripple across packaging and APIs. Rising government manufacturing incentives and preferential trade agreements lower landed-cost risk and reshape sourcing. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare spending and public campaigns\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGovernment promotion of self-care tends to shift demand from prescriptions to OTC, supporting Prestige’s OTC focus against a US health system that spent about 4.5 trillion dollars in 2022 (CMS); public funding of preventive campaigns increases demand in eye and oral care categories often targeted by $100s of millions in public programs; subsidized Rx alternatives can compress OTC volumes in specific segments, while policy-driven stockpiling causes temporary demand spikes seen in past crises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail and pricing oversight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cppolitical scrutiny of consumer prices can prompt hearings or voluntary caps that compress gross margins and force prestige to slow promotion cadence protect profitability major retailers cvs walgreens walmart control roughly u.s. pharmacy shelf space amplifying downstream negotiation pressure on vendors. transparency initiatives in including state-level pricing origin disclosure laws increase reporting costs may require clearer reshaping trade terms timing reported billion usd net sales fy2024 exposing material exposure retailer-driven margin pressure.\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRetailer concentration: CVS\/Walgreens\/Walmart ~60%\u003c\/li\u003e\n\u003cli\u003ePrestige FY2024 net sales ~1.1B USD\u003c\/li\u003e\n\u003cli\u003e2024 state pricing\/transparency laws rising — higher compliance costs\u003c\/li\u003e\n\u003cli\u003eResult: tighter promotion cadence, compressed vendor margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/ppolitical\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWorkforce and industrial policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmigration, labor and training policies shape availability of skilled manufacturing and QA staff for Prestige; US manufacturing employment ~12.5 million (BLS 2024), and tighter visa rules can raise hiring costs and time-to-fill critical roles.\u003c\/p\u003e\n\u003cp\u003eFederal incentives for advanced manufacturing (eg CHIPS funding ~52 billion USD) encourage automation capex; the 21% US federal corporate tax rate affects after-tax cash for M\u0026amp;A, while local content rules can force supply‑chain or footprint adjustments.\n\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eImmigration: affects skilled QA\/manufacturing hires\u003c\/li\u003e\n\u003cli\u003eIncentives: CHIPS ~52B supports automation\u003c\/li\u003e\n\u003cli\u003eTax: 21% federal rate alters M\u0026amp;A cash\u003c\/li\u003e\n\u003cli\u003eLocal content: may require facility shifts\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulation, tariffs and labor squeeze launches; retailer power \u003cstrong\u003e~60%\u003c\/strong\u003e, tax \u003cstrong\u003e21%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical shifts (FDA\/TGA enforcement, state pricing laws) alter launch timing and compliance costs; retailer concentration (CVS\/Walgreens\/Walmart ~60%) compresses margins vs Prestige FY2024 sales ~1.1B USD. Trade\/tariff disruptions and visa limits raise input and labor costs. Federal tax 21% and CHIPS ~52B affect cash for automation and M\u0026amp;A.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetailer concentration\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrestige FY2024 sales\u003c\/td\u003e\n\u003ctd\u003e~1.1B USD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS mfg employment (BLS 2024)\u003c\/td\u003e\n\u003ctd\u003e12.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCHIPS funding\u003c\/td\u003e\n\u003ctd\u003e~52B USD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFederal tax rate\u003c\/td\u003e\n\u003ctd\u003e21%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental forces uniquely affect Prestige Consumer Healthcare across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-driven trends and sector-specific examples. Designed for executives and investors, it highlights actionable risks, opportunities, and forward-looking insights to support strategy and funding decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented PESTLE summary of Prestige Consumer Healthcare that relieves pain by highlighting external risks, regulatory and market drivers for quick insertion into presentations or team planning; editable notes enable region- or product-specific context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer confidence and trading down\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMacro slowdowns and a 2024 Conference Board consumer confidence average near 102.7 pushed shoppers toward value packs and private label (private-label share ~18.6% in 2024), pressuring branded OTCs. Branded OTCs must defend price-premium with efficacy claims and trusted heritage to justify MSRP. Managing promotional depth and elasticity is critical to protect margins, while 2025 recovery cycles permit premiumization and mix improvement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflation and input costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAPI, excipient and packaging inflation have compressed Prestige Consumer Healthcare margins amid 3.4% US CPI in 2024; category pricing power varies with differentiation and retailer shelf dynamics. Hedging and multi-sourcing strategies blunt input volatility, while ongoing efficiency programs have helped sustain margin resilience during recent cost spikes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFX exposure (USD\/AUD)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRevenue and cost mismatches between USD and AUD materially influence Prestige Consumer Healthcare reported results as USD\/AUD moved roughly 7% year-over-year to about 1.60 by mid-2025, creating translation and transactional margin pressure. Currency swings compressed gross margins in Q2 2025 while natural hedges from offshore sourcing and financial hedging programs (forward contracts) reduced volatility. A geographically diversified portfolio mix, with key markets outside the US, helps buffer adverse moves.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetailer consolidation and terms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRetailer consolidation gives large chains and e-commerce platforms outsized leverage over slotting, MDF and returns policies, squeezing net pricing and pressuring working capital; the top 4 US retailers still account for roughly 40% of grocery sales, concentrating buyer power. Omnichannel growth (online share near 15% for CPG in 2024) rewards reliable fill rates and high-quality digital content while return\/MDF demands raise cost of trade. Diversifying channels reduces concentration risk and stabilizes margins.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSlotting\/MDF pressure: higher trade spend burden\u003c\/li\u003e\n\u003cli\u003eNet pricing: margin compression from tougher terms\u003c\/li\u003e\n\u003cli\u003eOmnichannel payoff: reliability + digital content = share gains\u003c\/li\u003e\n\u003cli\u003eMitigation: diversify channels to lower concentration risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest rates and M\u0026amp;A capacity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eUS policy rates at 5.25–5.50% (July 2025) raise debt service and compress M\u0026amp;A appetite, pushing acquirers to higher hurdle rates for brand deals and product launches. Deleveraging at target firms expands optionality during tightening, while effective synergy capture is pivotal to justify premiums and create post‑deal value.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFed funds 5.25–5.50% (Jul 2025)\u003c\/li\u003e\n\u003cli\u003eHigher cost of capital → higher hurdle rates\u003c\/li\u003e\n\u003cli\u003eLower leverage → more M\u0026amp;A flexibility\u003c\/li\u003e\n\u003cli\u003eSynergies essential to unlock deal value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulation, tariffs and labor squeeze launches; retailer power \u003cstrong\u003e~60%\u003c\/strong\u003e, tax \u003cstrong\u003e21%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConsumer confidence averaged 102.7 in 2024, driving value pack\/private‑label share (~18.6%) and pressuring branded OTCs; US CPI 3.4% in 2024 and input inflation compressed margins. Fed funds 5.25–5.50% (Jul 2025) raises cost of capital and slows M\u0026amp;A; USD\/AUD ≈1.60 mid‑2025 added translation pressure while top‑4 retailers ~40% share and online CPG ~15% reshape trade dynamics.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumer confidence (2024)\u003c\/td\u003e\n\u003ctd\u003e102.7\u003c\/td\u003e\n\u003ctd\u003eShift to value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrivate‑label share (2024)\u003c\/td\u003e\n\u003ctd\u003e18.6%\u003c\/td\u003e\n\u003ctd\u003eBranded pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS CPI (2024)\u003c\/td\u003e\n\u003ctd\u003e3.4%\u003c\/td\u003e\n\u003ctd\u003eInput cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed funds (Jul 2025)\u003c\/td\u003e\n\u003ctd\u003e5.25–5.50%\u003c\/td\u003e\n\u003ctd\u003eHigher hurdle rates\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUSD\/AUD (mid‑2025)\u003c\/td\u003e\n\u003ctd\u003e≈1.60\u003c\/td\u003e\n\u003ctd\u003eTranslation drag\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop‑4 retailers\u003c\/td\u003e\n\u003ctd\u003e≈40%\u003c\/td\u003e\n\u003ctd\u003eBuyer leverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnline CPG share (2024)\u003c\/td\u003e\n\u003ctd\u003e≈15%\u003c\/td\u003e\n\u003ctd\u003eOmnichannel importance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003ePrestige Consumer Healthcare PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown is the exact Prestige Consumer Healthcare PESTLE Analysis you’ll receive after purchase, fully formatted and ready to use. It contains the complete political, economic, social, technological, legal, and environmental assessment. No placeholders or teasers—this is the final, downloadable file. You’ll get this identical document immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56162525806969,"sku":"prestigeconsumerhealthcare-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/prestigeconsumerhealthcare-pestle-analysis.png?v=1762702364","url":"https:\/\/portersfiveforce.com\/products\/prestigeconsumerhealthcare-pestle-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}